Evommune

EVMN · NYSE

$5.38+$0.11 (+2.09%)TodayMarket closed · Oct 20, 7:50 PM ET

Prev close $5.27

Latest news

Press releaseOct 1, 8:00 AM ETBusiness Wire
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Press releaseSep 23, 4:05 PM ETBusiness Wire
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
NewsSep 9, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsSep 9, 8:06 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsSep 9, 7:40 AM ETVandana Singh
Evommune Halts Atopic Dermatitis Program Following Trial Failure
Press releaseSep 8, 5:43 PM ETBusiness Wire
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Press releaseAug 6, 4:05 PM ETBusiness Wire
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Press releaseJul 30, 8:00 AM ETBusiness Wire
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Press releaseJul 7, 2:08 PM ETPRNewswire
Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky
NewsJul 6, 6:11 AM ETAvi Kapoor
Top 3 Health Care Stocks That May Rocket Higher In July
Press releaseJun 30, 1:39 PM ETPRNewswire
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)
NewsJun 29, 12:36 PM ETVandana Singh
Evommune's Skin Disorder Study Falls Short
NewsJun 29, 12:30 PM ETAvi Kapoor
Crude Oil Gains 2%; Comcast Shares Spike Higher
Press releaseJun 29, 8:30 AM ETBusiness Wire
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Press releaseMay 7, 4:05 PM ETBusiness Wire
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Press releaseApr 6, 9:00 AM ETBusiness Wire
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Press releaseMar 5, 4:01 PM ETBusiness Wire
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
NewsFeb 15, 9:59 AM ETChris Katje
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Press releaseFeb 12, 8:30 PM ETBusiness Wire
Evommune Announces $125 Million Private Placement
NewsFeb 12, 9:46 AM ETVandana Singh
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial
NewsFeb 10, 12:16 PM ETAvi Kapoor
Gold Moves Lower; CVS Health Earnings Top Views
NewsFeb 10, 12:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsFeb 10, 10:56 AM ETAvi Kapoor
Datadog, Spotify, Marriott, Ferrari And Other Big Stocks Moving Higher On Tuesday
NewsFeb 10, 9:56 AM ETAvi Kapoor
Dow Surges Over 200 Points; Coca-Cola Posts Mixed Q4 Results
Press releaseFeb 10, 7:30 AM ETBusiness Wire
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
NewsJan 6, 7:50 AM ETAvi Kapoor
This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
NewsDec 19, 12:07 PM ETAvi Kapoor
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday
Press releaseDec 11, 4:05 PM ETBusiness Wire
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
NewsDec 1, 1:58 PM ETVandana Singh
Evommune's Skin Disorder Candidate Has 'Blockbuster Commercial Opportunity': Analyst Projects $5 Billion Peak Sales
NewsDec 1, 9:09 AM ETAvi Kapoor
This Joby Aviation Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Press releaseNov 6, 8:55 AM ETPRNewswire
NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading
Press releaseNov 5, 7:45 PM ETPRNewswire
Evommune Announces Pricing of its Initial Public Offering
Press releaseNov 5, 7:45 PM ETPRNewswire
Evommune Announces Pricing of its Initial Public Offering
Press releaseOct 30, 6:30 AM ETPRNewswire
Evommune Announces Commencement of Initial Public Offering

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Evommune Halts Atopic Dermatitis Program Following Trial Failure

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky

Top 3 Health Care Stocks That May Rocket Higher In July

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)

Evommune's Skin Disorder Study Falls Short

Crude Oil Gains 2%; Comcast Shares Spike Higher

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Evommune Announces $125 Million Private Placement

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Gold Moves Lower; CVS Health Earnings Top Views

12 Health Care Stocks Moving In Tuesday's Intraday Session

Datadog, Spotify, Marriott, Ferrari And Other Big Stocks Moving Higher On Tuesday

Dow Surges Over 200 Points; Coca-Cola Posts Mixed Q4 Results

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Evommune's Skin Disorder Candidate Has 'Blockbuster Commercial Opportunity': Analyst Projects $5 Billion Peak Sales

This Joby Aviation Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading

Evommune Announces Pricing of its Initial Public Offering

Evommune Announces Pricing of its Initial Public Offering

Evommune Announces Commencement of Initial Public Offering